153 results
8-K
EX-99.1
FENC
Fennec Pharmaceuticals Inc
25 Mar 24
Fennec Pharmaceuticals Reports Full Year and Fourth Quarter 2023 Financial Results and Provides Business Update
4:05pm
in pediatric patients.7 PEDMARK is also the only therapeutic agent with proven efficacy and safety data with an established dosing paradigm, across … month of age and older with localized, non-metastatic solid tumors.
Limitations of Use
The safety and efficacy of PEDMARK have not been established
8-K
EX-10.1
ndi1q8my ptgt1
21 Mar 24
Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand
4:02pm
8-K
EX-99.1
qjb1qh4yt0c2vjw
21 Mar 24
Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand
4:02pm
8-K/A
EX-99.1
qz1382mollffmi ky
6 Mar 24
Fennec Pharmaceuticals Reports Preliminary Unaudited Net Revenue for Fourth Quarter and Full-Year 2023 Results
4:07pm
8-K
EX-99.1
xqdxs21 ib
29 Feb 24
Fennec Pharmaceuticals Reports Preliminary Unaudited Net Revenue for Fourth Quarter and Full-Year 2023 Results
4:04pm
8-K
EX-99.1
r7959t4cz2d318
5 Dec 23
Fennec Announces Incremental $5 Million Investment from Petrichor
8:51pm
8-K
EX-99.1
34dkliu6oxlly6lk7p
6 Nov 23
Fennec Pharmaceuticals Announces Third Quarter 2023
7:38pm
8-K/A
EX-99.1
o2g0qf
7 Aug 23
Fennec Pharmaceuticals Announces Second Quarter 2023
10:51am
8-K
EX-99.1
8grmvmullx
4 Aug 23
Fennec Pharmaceuticals Announces Second Quarter 2023
10:58am
8-K
EX-99.1
g98r3xn n7
4 Aug 23
Fennec Pharmaceuticals Announces Second Quarter 2023
10:57am
8-K
EX-99.1
vlgu2
6 Jun 23
Other Events
5:39pm